Drug Target Review – Issue #3 2016
Posted: 20 September 2016 | Drug Target Review | No comments yet
In Issue #3 2016: Flow Cytometry, Enzymes, Imaging, GPCRs, Hit-To-Lead, CNS, Companion Diagnostics, and much more…
In Issue #3 2016 of Drug Target Review:
- FOREWORD: Paying to be obvious – ingenuity and patent law
Jacob Gifford Head, Thomas More Chambers - FLOW CYTOMETRY: Breaking bottlenecks in drug discovery and development
Pushpanathan Muthuirulan, National Institutes of Health and Pooja Sharma, University of Maryland - ENZYMES: Switching on genes regulating oxysterol synthesis – a therapeutic option?
Steve Meaney, Dublin Institute of Technology - IMAGING IN-DEPTH FOCUS
With articles from Norman Peterson, MedImmune/AstraZeneca, and Janet Brownlees, Emilie Bureau, Jenny Cook and Debra Taylor, MRC Technology - GPCRs: High-throughput calcium flux assays – luminescent versus fluorescent readout
Nicolas Houvenaghel, Jans Mia, Van der Schueren Jan and Christophe Thierry, Galapagos NV - HIT-TO-LEAD IN-DEPTH FOCUS
With contributions from Douglas B. Kitchen and Mark Wolf, Albany Molecular Research, and Martina Fenske and Sheraz Gul, Fraunhofer IME - CNS: Fibromyalgia pathogenesis provides drug target clues
Kim Lawson, Sheffield Hallam University - COMPANION DIAGNOSTICS
Interview with Pierre Belichard, CEO of Enterome Biosciences
Issue #3 2016 is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
